Literature DB >> 27046319

Neurobiology of depression and mechanism of action of depression treatments.

Pierre Blier.   

Abstract

Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), may alleviate depressive symptoms but also leave residual symptoms. The mechanism of action of SSRIs increases serotonin (5-HT) activity but decreases norepinephrine (NE) and dopamine (DA) activity. By engaging additional targets (eg, NE, DA) along with 5-HT, clinicians may help patients with residual symptoms and treatment-resistant depression. Dual-acting agents and combination strategies can be used to target specific symptoms or block/activate specific receptors for broader therapeutic benefits. Clinicians who understand the mechanism of action of antidepressants can switch or combine agents as needed to help patients achieve complete remission. © Copyright 2016 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27046319     DOI: 10.4088/JCP.13097tx3c

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  17 in total

1.  Anti-depressive-like behaviors of APN KO mice involve Trkb/BDNF signaling related neuroinflammatory changes.

Authors:  Weifen Li; Tahir Ali; Chengyou Zheng; Kaiwu He; Zizhen Liu; Fawad Ali Shah; Ningning Li; Zhi-Jian Yu; Shupeng Li
Journal:  Mol Psychiatry       Date:  2021-10-12       Impact factor: 15.992

Review 2.  Molecular Mechanisms Associated with Antidepressant Treatment on Major Depression.

Authors:  Lívia Ramos-da-Silva; Pamela T Carlson; Licia C Silva-Costa; Daniel Martins-de-Souza; Valéria de Almeida
Journal:  Complex Psychiatry       Date:  2021-07-09

Review 3.  Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression?

Authors:  Fangyi Zhao; Ziqian Cheng; Jingjing Piao; Ranji Cui; Bingjin Li
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

4.  Stress-induced despair behavior develops independently of the Ahr-RORγt axis in CD4 + cells.

Authors:  Courtney R Rivet-Noor; Andrea R Merchak; Sihan Li; Rebecca M Beiter; Sangwoo Lee; Jalon Aaron Thomas; Anthony Fernández-Castañeda; Jung-Bum Shin; Alban Gaultier
Journal:  Sci Rep       Date:  2022-05-21       Impact factor: 4.996

Review 5.  Anti-Depressant Properties of Crocin Molecules in Saffron.

Authors:  Shahida Anusha Siddiqui; Ali Ali Redha; Edgar Remmet Snoeck; Shubhra Singh; Jesus Simal-Gandara; Salam A Ibrahim; Seid Mahdi Jafari
Journal:  Molecules       Date:  2022-03-23       Impact factor: 4.411

6.  Puerarin ameliorated the behavioral deficits induced by chronic stress in rats.

Authors:  Zhi-Kun Qiu; Guan-Hua Zhang; De-Sheng Zhong; Jia-Li He; Xu Liu; Ji-Sheng Chen; Da-Nian Wei
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

7.  miR-16 and Fluoxetine Both Reverse Autophagic and Apoptotic Change in Chronic Unpredictable Mild Stress Model Rats.

Authors:  Yang Yang; Zhiying Hu; Xiaoxue Du; Henry Davies; Xue Huo; Marong Fang
Journal:  Front Neurosci       Date:  2017-07-25       Impact factor: 4.677

8.  Huanglian-Jie-Du-Tang Extract Ameliorates Depression-Like Behaviors through BDNF-TrkB-CREB Pathway in Rats with Chronic Unpredictable Stress.

Authors:  Yi-Lu Ye; Kai Zhong; Dan-Dan Liu; Jing Xu; Bei-Bei Pan; Xiang Li; Yue-Ping Yu; Qi Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2017-06-14       Impact factor: 2.629

9.  Chaihu-Shugan-San exerts an antidepressive effect by downregulating miR-124 and releasing inhibition of the MAPK14 and Gria3 signaling pathways.

Authors:  Qiong Liu; Ning-Ning Sun; Zheng-Zhi Wu; Da-Hua Fan; Mei-Qun Cao
Journal:  Neural Regen Res       Date:  2018-05       Impact factor: 5.135

10.  Therapeutic Targets and Mechanism of Xingpi Jieyu Decoction in Depression: A Network Pharmacology Study.

Authors:  Ze Chang; Li-Juan He; Dang-Feng Tian; Qiang Gao; Jing-Feng Ling; Yu-Chun Wang; Zhen-Yun Han; Rong-Juan Guo
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-23       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.